All Stories

  1. Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Cancer?
  2. Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Can-Cer?
  3. VCAN is essential for ERK5-driven tumorigenesis in soft tissue sarcoma
  4. BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake
  5. Exploring the Gut Microbiota–Retina Axis: Implications for Health and Disease
  6. The MEK5/ERK5 pathway promotes the activation of the Hedgehog/GLI signaling in melanoma cells
  7. Liquid Crystalline Networks Hamper the Malignancy of Cancer Cells
  8. Ganglioside GD2 Contributes to a Stem‐Like Phenotype in Intrahepatic Cholangiocarcinoma
  9. Altered fatty acid metabolism rewires cholangiocarcinoma stemness features
  10. ERK5 mediates pro-tumorigenic phenotype in non-small lung cancer cells induced by PGE2
  11. Latent-Transforming Growth Factor β-Binding Protein 1/Transforming Growth Factor β1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma
  12. Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation
  13. Sphingosine 1‐phosphate elicits a ROS‐mediated proinflammatory response in human endometrial stromal cells via ERK5 activation
  14. Pathophysiological Impact of the MEK5/ERK5 Pathway in Oxidative Stress
  15. Anti‐β4 integrin autoantibodies in patients with mucous membrane pemphigoid: A retrospective analysis from a tertiary centre in Italy
  16. MAPK15 protects from oxidative stress‐dependent cellular senescence by inducing the mitophagic process
  17. Targeting MAPK in Cancer 2.0
  18. Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction
  19. Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators
  20. Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation
  21. Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
  22. The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells
  23. Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential
  24. Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells
  25. Playing the Whack-A-Mole Game: ERK5 Activation Emerges Among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2- Targeted Therapy
  26. Enhanced Antitumoral Activity and Photoacoustic Imaging Properties of AuNP‐Enriched Endothelial Colony Forming Cells on Melanoma
  27. In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
  28. Abstracts of the 2nd AMP Europe Congress
  29. Fatty acids regulate the biology of cholangiocarcinoma cells
  30. Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy
  31. The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells
  32. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma
  33. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells
  34. Poster Presentations: Posters Saturday, 13 April 2019
  35. Impact of ERK5 on the Hallmarks of Cancer
  36. Ganglioside composition correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cell adhesion
  37. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells
  38. ERK5 is activated by oncogenic BRAF and promotes melanoma growth
  39. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine
  40. The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
  41. Low-dose methotrexate enhances cycling of highly anaplastic cancer cells
  42. Different BCR/Abl protein suppression patterns as a converging trait of Chronic Myeloid Leukemia cell adaptation to energy restriction
  43. Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway
  44. Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells
  45. Crosstalk between MAPK and HH_GLI signaling in cancer
  46. The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents
  47. Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells
  48. PGE2 synergizes with CSF-1R
  49. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells
  50. Positive correlation of HIF2α and SERPINB3 in human hepatocellular carcinoma: selectivity and prognostic implications
  51. Colony-Stimulating Factor-1 Receptor in the Polarization of Macrophages: A Target for Turning Bad to Good Ones?
  52. Lipid rafts: integrated platforms for vascular organization offering therapeutic opportunities
  53. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy
  54. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma
  55. 786: The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma
  56. Possible mechanisms and function of nuclear trafficking of the colony-stimulating factor-1 receptor
  57. P94 c-Rel AND p27Kip ARE DOWNSTREAM TARGETS OF ERK5 IN HEPATOCELLULAR CARCINOMA (HCC) IN VIVO AND IN VITRO
  58. One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment
  59. Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells
  60. Correction to Barbetti V, et al. Epigenetics Volume 8, Issue 2; pp. 210–9
  61. Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets
  62. The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
  63. 1039 ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN KINASE ERK5 REGULATES THE DEVELOPMENT AND GROWTH OF HEPATOCELLULAR CARCINOMA
  64. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia
  65. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells
  66. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming
  67. 78O_PR The Role of Ap-1 in Endocrine-Resistant Breast Cancer
  68. The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines
  69. Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
  70. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate
  71. Correction: Granulocyte Maturation after Butyrate Treatment of Leukemic Blasts
  72. p38 and cancer: Yang gets yin
  73. ERK5/BMK1 Is Indispensable for Optimal Colony-Stimulating Factor 1 (CSF-1)-Induced Proliferation in Macrophages in a Src-Dependent Fashion
  74. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells
  75. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells
  76. Severe Hypoxia Defines Heterogeneity and Selects Highly Immature Progenitors Within Clonal Erythroleukemia Cells
  77. The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells
  78. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations
  79. 332 Activation of ERK5, a member of the mapk family, differentially regulates proliferation and migration of hepatic stellate cells
  80. Focal adhesion kinase is redistributed to focal complexes and mediates cell spreading in macrophages in response to M-CSF
  81. Corrections
  82. Tryptophan availability selectively limits NO-synthase induction in macrophages
  83. Low M r Phosphotyrosine Protein Phosphatase Associates and Dephosphorylates p125 Focal Adhesion Kinase, Interfering with Cell Motility and Spreading
  84. Opposite effects of different doses of MCSF on ERK phosphorylation and cell proliferation in macrophages
  85. Transmodulation of Cell Surface Regulatory Molecules via Ectodomain Shedding
  86. TNF- -Converting Enzyme Cleaves the Macrophage Colony-Stimulating Factor Receptor in Macrophages Undergoing Activation
  87. The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability
  88. Incubation of murine bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors
  89. Low M r phosphotyrosine protein phosphatase activity on fibroblast growth factor receptor is not associated with enzyme translocation
  90. The Low-Molecular-Weight Phosphotyrosine Protein Phosphatase, when Overexpressed, Reduces the Mitogenic Response to Macrophage Colony-Stimulating Factor and Tyrosine Phosphorylation of Its Receptor
  91. INTERLEUKIN 2 DOWN-MODULATES THE MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR IN MURINE MACROPHAGES